EAU25: Telix presents at Europe’s largest urological event
Join Telix this week at the 40th Annual European Association of Urology Congress (EAU25) being held in Madrid, Spain.
Telix’s Phase 3 ProstACT Global study of lead PSMA-targeting radio antibody-drug conjugate candidate TLX591 will be presented alongside a series of presentations on SENSEI®, Telix’s miniature robotic-assisted gamma probe for radio-guided surgery.
Congress details:
IFEMA MADRID
Avda del Partenón 5
Madrid, Spain
21 – 24 March 2025
The full congress schedule can be viewed here
San Raffaele, Milan
ProstACT Global – a Phase 3 Study with standard of care with and without 177Lu-rosopatamab (TLX591) for patients with metastatic castration resistant prostate cancer progressing despite treatment with a novel androgen axis drug
Abstract: A0080
Hospital del Mar, Barcelona
Implementation of the sentinel lymph node technique in the surgical management of muscle invasive bladder cancer and evaluation of the use of the SENSEI® flexible gamma probe in robotic radical cystectomy
Abstract: V092
University Medical Center Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center, Hamburg
Robot-assisted PSMA-radioguided surgery for local recurrence after radical prostatectomy with or without subsequent radiation therapy
Abstract: V093
University Medical Center Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center, Hamburg
Robot-assisted PSMA-radioguided salvage surgery for oligorecurrent prostate cancer using the novel SENSEI® gamma probe: correlation of intraoperative measurements to preoperative imaging and final histology
Abstract: A0632